Analysts Have Conflicting Sentiments on These Healthcare Companies: Arbutus Biopharma (ABUS), BioMarin Pharmaceutical (BMRN) and Enovis (ENOV)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Arbutus Biopharma (ABUS – Research Report), BioMarin Pharmaceutical (BMRN – Research Report) and Enovis (ENOV – Research Report).

Arbutus Biopharma (ABUS)

In a report issued on August 4, Brian Skorney from Robert W. Baird maintained a Hold rating on Arbutus Biopharma, with a price target of $4.00. The company’s shares closed last Thursday at $2.47, close to its 52-week low of $1.93.

According to TipRanks.com, Skorney has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -4.9% and a 45.3% success rate. Skorney covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Enanta Pharmaceuticals, and Vertex Pharmaceuticals.

Currently, the analyst consensus on Arbutus Biopharma is a Strong Buy with an average price target of $6.63.

See Insiders’ Hot Stocks on TipRanks >>

BioMarin Pharmaceutical (BMRN)

In a report issued on August 4, Joel Beatty from Robert W. Baird maintained a Buy rating on BioMarin Pharmaceutical, with a price target of $112.00. The company’s shares closed last Thursday at $95.07, close to its 52-week high of $97.76.

According to TipRanks.com, Beatty is a 4-star analyst with an average return of 6.2% and a 51.9% success rate. Beatty covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Ultragenyx Pharmaceutical, and Syndax Pharmaceuticals.

BioMarin Pharmaceutical has an analyst consensus of Strong Buy, with a price target consensus of $110.00, which is a 15.0% upside from current levels. In a report issued on August 1, J.P. Morgan also initiated coverage with a Buy rating on the stock with a $140.00 price target.

Enovis (ENOV)

Robert W. Baird analyst Jeff Johnson maintained a Buy rating on Enovis on August 4 and set a price target of $73.00. The company’s shares closed last Thursday at $58.56.

According to TipRanks.com, Johnson is a 5-star analyst with an average return of 18.7% and a 55.2% success rate. Johnson covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Tandem Diabetes Care, and Patterson Companies.

Currently, the analyst consensus on Enovis is a Moderate Buy with an average price target of $67.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ABUS:

• Analysts Offer Insights on Consumer Goods Companies: Hamilton Beach Brands Holding Company (HBB), Wayfair (W) and BellRing Brands (BRBR)
• Analysts Offer Insights on Utilities Companies: Murphy Oil (MUR) and Western Midstream Partners (WES)
• Analysts’ Top Services Picks: Shake Shack (SHAK)
• Analysts Offer Insights on Materials Companies: and Linde (LIN)
• Britain’s economy contracts 0.1% amid inflation and recession fears